References
  1. Ljungman P, Bregni M, Brune M, Cornelissen J, De Witte T, Dini G et al. Allogeneic and autologous transplantation for haematologic diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010;45(2):219-234.
  2. Passweg J, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplant. 2019;54:1575-1585.
  3. Gooptu M, Koreth J. Translational and clinical advances in acute graft-versus-host disease. Haematologica 2020 Nov 1;105(11):2550-2560. doi:10.3324/haematol.2019.240309.
  4. MacDonald K, Hill G, Blazer B. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 2017;129:13-21.
  5. Zecca M, Prete A, Rondelli R, Lanino E, Balduzzi A, Messina C et al. Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome. Blood. 2002;100:1192-1200.
  6. Pulsipher M, Langholz B, Wall D, Schultz K, Bunin N, Carroll W, et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology/Pediatric Blood and Marrow Transplant Consortium trial. Blood.2014 Mar 27;123(13):2017-25.
  7. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: Working Definitions. Biol Blood Marrow Transplant 2009; 15:1628-33.
  8. Przepiorka D, Weisdorf D, Martin R, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on Acute GVHD Grading. Bone Marrow Transplant.1995;15:825-8.
  9. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med.1980;69:204-17.
  10. Umeda K, Imai K, Yanagimachi M, Yabe H, Kobayashi M, Takahashi Y, et al. Impact of graft-versus-host disease on the clinical outcome of allogeneic hematopoietic stem cell transplantation for non-malignant diseases. International Journal of Hematology 2020;111:869-876.
  11. Mahmoud H, Elhaddad A, Fahmy O, Samra M, Abdelfattah R, El-Nahass Y, et al. Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders. Journal of Advanced Research. 2015;6:449-438.
  12. Jacobsohn D, Arora M, Klein J, Hassebroek A, Flowers M, Cutler C et al. Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. Blood. 2011;118:4472-4479.
  13. Bertaina M, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta-T and B cells in children with non-malignant disorders. Blood. 2014;124(5):822-6.
  14. Zecca M, Strocchio L, Pagliara D, Comoli P, Bertaina A, Giorgiani G, et al. HLA-haploidentical T-cell depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia. Biol Blood Marrow Transplant. 2014;20(4):571-6.
  15. Anurathapan U, Hongeng S, Pakakasama S, Sirachainan N, Songdej D, Chuansumrit A, et al. Hematopoietic stem cell transplantation for homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients from haploidentical donors. Bone Marrow Transplant. 2016;51(6):813-8.
  16. Chellapandian D, Sunkersett G, Oshrine B, Galvez Silva J, Ziga E, Alperstein W, et al. Pediatric HCT in Florida (2014-2016): A Report from the FPBCC. Pediatric Transplant. 2020 Nov 27;313931. Doi: 10.1111/petr.13931Horan J, Wang T, Haagenson M, Spellman S, Dehn J, Eapen M, et al. Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for non-malignant disorders. Blood. 2012;120:2918-2924.
  17. Ngwube A, Shah N, Jacobsohn D, Ziga D, Shenoy S. Abatacept is effective for Gvhd prophylaxis after unrelated donor stem cell transplantation (URD SCT) for severe sickle cell disease. Blood 2019 134 (Supplement_1:370). https://doi.org/10.1182/blood-2019-126405.
  18. Bertaina A, Pitisci A, Sinibaldi M, Algeri M. T Cell-depleted and T cell-replete HLA-Haploidentical stem cell transplantation for non-malignant disorders. Curr Hematol Malig Rep. 2017;12:68-78.
  19. Arcuri L, Nabhan S, Cunha R, Nichele S, Ribeiro A, Fernandes J, et al. Impact of CD34 cell dose and conditioning regimen on outcomes after haploidentical donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for relapsed/refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2020;26:2311-2317.
  20. Even-Or E, NaserEddin A, Schejter YD, Shadur B, Zaidman I and Stepensky P. Bone Marrow Transplant. 2020. https://doi.org/10.1038/s41409-020-01040-9.
  21. Yu J, Black V, Lamba J, Horn B. Potential risk factors associated with graft failure of haploidentical hematopoietic stem cell transplantation (HSCT) in Children with sickle cell disease (SCD). J Pediatr Hematol Oncol. 2020 Jun 26. doi:10.1097/MPH.0000000000001873. Figure Legends: FIGURE 1 Overall survival by acute GVHD grade FIGURE 2 Overall survival by chronic GVHD grade Data: The data that support the findings of this study are available from the corresponding author upon a reasonable request. .